middle.news
How Recce Pharmaceuticals’ $5.3m R&D Rebate Fuels Anti-Infective Breakthroughs
10:52am on Wednesday 14th of January, 2026 AEDT
•
Healthcare
Read Story
How Recce Pharmaceuticals’ $5.3m R&D Rebate Fuels Anti-Infective Breakthroughs
10:52am on Wednesday 14th of January, 2026 AEDT
Key Points
AUD $5.3 million R&D tax rebate received for FY2025
Additional $3 million rebate pending Australian Taxation Office approval
Funds to support Phase 3 clinical trial in Indonesia and domestic programs
Rebate reflects 43.5% of eligible R&D activities conducted locally and overseas
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Recce Pharmaceuticals (ASX:RCE)
OPEN ARTICLE